[Inhibitory effect of daunorubicin enhanced by PDTC on drug-resistant leukemic cells in vitro].
To investigate the chemosensitizing effect of pyrroledithiocarbomate (PDTC) on daunorubicin in drug-resistant leukemic cells in vitro, MTT method was used to observe the changes of the proliferation of intractable leukemia MNC treated with daunorubicin (30 microg/ml) combined with PDTC (25, 50 or 100 micromol/L). The results showed that inhibiting rate of daunorubicin combined with PDTC(25, 50 or 100 micromol/L) on drug-resistant leukemic cells was significantly higher than that of daunorubicin alone (P < 0.05). Among the three different doses of PDTC, the concentration of 50 micromol/L of PDTC inhibited the proliferation of drug-resistant leukemic cells significantly. In conclusion, PDTC can sensitize anti-tumor effect of daunorubicin in vitro. The concentration of 50 micromol/L of PDTC has stronger chemosensitizing effect on daunorubicin than that of the other concentrations of PDTC (25 micromol/L or 100 micromol/L) in vitro.
Lei
Hu-Yi
HY
Department of Hematology, Xiangya Hospital, Central Southern University, Changsha 410008, China.
Zhao
Xie-Lan
XL
Xiao
Xi-Bin
XB
D000970:Antineoplastic Agents / Q000494:pharmacology; D001854:Bone Marrow Cells / Q000187:drug effects / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects*; D003630:Daunorubicin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D006801:Humans; D007938:Leukemia / Q000097:blood* / Q000473:pathology; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000473:pathology; D011392:Proline / Q000031:analogs & derivatives* / Q000494:pharmacology; D013859:Thiocarbamates / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D013859:Thiocarbamates; C066229:prolinedithiocarbamate; D011392:Proline; D003630:Daunorubicin